The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 62, Issue 3, 2006, Pages 336-344

  Adkison, Kimberly K ^a   Shachoy Clark, Anne ^a   Fang, Lei ^a   Lou, Yu ^a   Otto, Vicky R ^a   Berrey, M Michelle ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Aplaviroc; CCR5; Drug interaction; Lopinavir; Ritonavir

Indexed keywords

APL 873140; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 3A; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME SUBSTRATE; ERYTHEMA; FEMALE; FLATULENCE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LOOSE FECES; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; REGRESSION ANALYSIS; SINGLE DRUG DOSE; STEADY STATE; VOMITING;

ADOLESCENT; ADULT; ANIMALS; BENZOATES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICE; MIDDLE AGED; PIPERAZINES; PYRIMIDINONES; RATS; RECEPTORS, CCR5; RITONAVIR; SPIRO COMPOUNDS;

EID: 33747035926     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02661.x     Document Type: Article

References (17)

1. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004; 14: 255-70.
2. Demarest J, Shibayama S, Ferris R, Vavro C, StClair M, Boone L. A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity. In Program and Abstracts of the XV International AIDS Conference (Bangkok, Thailand), July 11-16, 2004. Weora1231 2004.
3. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67: 1268-82.
4. Adkison K, Shachoy-Clark A, Fang L, Lou Y, O'Mara K, Berrey M, Piscitelli SC. Pharmacokinetics and short term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob Agents Chemother 2005; 49: 2802-6.
5. Adkison K, Song I, Fang L, Bernstein J, Shachoy-Clark AL, Lou Y, Berrey M, Piscitelli SC. The effect of food and formulation on the pharmacokinetics of the novel CCR5 antagonist 873140. In Program and Abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Infection (Quebec, Canada), April 28-30, 2005. Virol Educ 2005; 6.7.
6. Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005; 19: 1443-8.
7. Adkison K, Lou Y, Fang L, Shachoy-Clark A, Demarest J, Berrey M, Piscitelli S. Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel CCR5 antagonist, 873140, during a 10-day monotherapy study in HIV-infected subjects. In Program and Abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy (Quebec, Canada). Virol Educ 2005; 77.
8. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clincal pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
9. 9a King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet 2004; 43: 291-310.
10. Cvetkovic RS, Goa KL. Lopinavir/ritonavir. A review of its use in the management of HIV infection. Drugs 2003; 63: 769-802.
11. Perloff MD, von Moltke LL, Marchand JE, Greenblatt DJ. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001; 90: 1829-37.
12. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-13.
13. Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005; 312: 583-91.
14. Hsu A, Granneman GR, Cao G, Carothers L, El Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-64.
15. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52: 255-64.
16. Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y, Berrey M, Nafziger A, Piscitelli S, Bertino J. 873140, a novel CCR5 antagonist, does not significantly interact with major drug metabolizing enzymes. In Program and Abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Infection (Quebec, Canada). Virol Educ 2005; 75.
17. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the 'Cooperstown 5+1 cocktail'. Clin Pharmacol Ther 2003; 74: 437-47.